Completed PHASE3 INTERVENTIONAL 2-arm NCT00002836

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

A Phase III Randomized Comparison of High Dose Chemotherapy G-CSF To G-CSF For Mobilization of Peripheral Blood Stem Cells For Autologous Transplantation For Patients With Responsive Metastatic Breast Cancer Or High Risk Stage II-III Patients

Sponsor: M.D. Anderson Cancer Center

Conditions Breast Cancer

Interventions Carmustine Cisplatin Cyclophosphamide (CTX) Etoposide Filgrastim (G-CSF) Peripheral Blood Stem Cell Transplantation Thiotepa

Updated 6 times since 2017 Last updated: Nov 5, 2018 Started: Sep 26, 1995 Primary completion: Mar 9, 2006 Completion: Mar 9, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Breast Cancer, this trial is completed. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 6 data snapshots since 1995. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Dec 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States